Q-omics provides the consensus-scored ZNF264 profile across patient tissues and cancer cell-line models. ZNF264 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF264 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF264 RNA expression shows 21,365 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where ZNF264 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF264 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF264 survival associations across molecular data types. ZNF264 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF264 RNA expression–survival associations across cancer types. High ZNF264 expression shows unfavorable associations in LGG, CESC and ACC, but favorable associations in HNSC, SCLC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF264 RNA expression.
This table summarizes ZNF264 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF264. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF264 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, LIHC, CHOL and BRCA. The HNSC box plot shows higher ZNF264 RNA expression in tumor versus normal tissue (log2 FC = +0.359, t-test p = .001).
This table shows molecular features associated with ZNF264 in patient tissues and cancer cell lines. In patient samples, ZNF264 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF264 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
